Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 24;139(12):1908-1919.
doi: 10.1182/blood.2021013290.

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Mahmoud R Gaballa  1 , Pinaki Banerjee  2 , Denái R Milton  3 , Xianli Jiang  4 , Christina Ganesh  2 , Sajad Khazal  5 , Vandana Nandivada  2 , Sanjida Islam  2 , Mecit Kaplan  2 , May Daher  2 , Rafet Basar  2 , Amin Alousi  2 , Rohtesh Mehta  2 , Gheath Alatrash  2 , Issa Khouri  2 , Betul Oran  2 , David Marin  2 , Uday Popat  2 , Amanda Olson  2 , Priti Tewari  5 , Nitin Jain  6 , Elias Jabbour  6 , Farhad Ravandi  6 , Hagop Kantarjian  6 , Ken Chen  4 , Richard Champlin  2 , Elizabeth Shpall  2 , Katayoun Rezvani  2 , Partow Kebriaei  2
Affiliations

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Mahmoud R Gaballa et al. Blood. .

Abstract

Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 study evaluating the feasibility of 4 cycles of blinatumomab administered every 3 months during the first year after HCT in an effort to mitigate relapse in high-risk ALL patients. Twenty-one of 23 enrolled patients received at least 1 cycle of blinatumomab and were included in the analysis. The median time from HCT to the first cycle of blinatumomab was 78 days (range, 44 to 105). Twelve patients (57%) completed all 4 treatment cycles. Neutropenia was the only grade 4 adverse event (19%). Rates of cytokine release (5% G1) and neurotoxicity (5% G2) were minimal. The cumulative incidence of acute graft-versus-host disease (GVHD) grades 2 to 4 and 3 to 4 were 33% and 5%, respectively; 2 cases of mild (10%) and 1 case of moderate (5%) chronic GVHD were noted. With a median follow-up of 14.3 months, the 1-year overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) rates were 85%, 71%, and 0%, respectively. In a matched analysis with a contemporary cohort of 57 patients, we found no significant difference between groups regarding blinatumomab's efficacy. Correlative studies of baseline and posttreatment samples identified patients with specific T-cell profiles as "responders" or "nonresponders" to therapy. Responders had higher proportions of effector memory CD8 T-cell subsets. Nonresponders were T-cell deficient and expressed more inhibitory checkpoint molecules, including T-cell immunoglobulin and mucin domain 3 (TIM3). We found that blinatumomab postallogeneic HCT is feasible, and its benefit is dependent on the immune milieu at time of treatment. This paper is posted on ClinicalTrials.gov, study ID: NCT02807883.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Heatmap of surface marker expression of T cells in nonresponders and responders. Hyperbolic arcsin transformed fluorochrome expression for 14 markers were averaged for baseline samples taken from nonresponders (n = 3) and responders (n = 10), and posttreatment samples from nonresponders (n = 4) and responders (n = 11).
Figure 2.
Figure 2.
Subpopulations identified via viSNE analysis of 14 surface markers in all 56 samples. (A) viSNE map for nonresponders and responders color-coded according to PhenoGraph cluster annotation. viSNE maps were separated to baseline and posttreatment in both nonresponders and responders groups. (B) Heatmap of mean surface marker expression in each cluster. Percentage in parentheses denotes the size of each cluster.
Figure 3.
Figure 3.
Study outcomes for patients treated with blinatumomab. At 1 year, the rate of relapse was 29% (95% CI, 11%-49%) (A), progression-free survival (PFS) 71% (95% CI, 47%-86%) (B), and overall survival (OS) 85% (95% CI, 61%-95%) (C).
Figure 4.
Figure 4.
Comparison of PFS and OS between patients treated with blinatumomab maintenance and no posttransplant maintenance (matched-case cohort). At 1 year, the rates of PFS for the blinatumomab vs the control group were 71% vs 68%, P = .44 (A), and the rates for OS for the blinatumomab vs the control group were 85% vs 76%, P = .23 (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Goldstone AH, Richards SM, Lazarus HM, et al. . In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827-1833. - PubMed
    1. Fielding AK, Rowe JM, Richards SM, et al. . Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489-4496. - PMC - PubMed
    1. Gökbuget N, Kneba M, Raff T, et al. ; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia . Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9): 1868-1876. - PubMed
    1. Zhou Y, Slack R, Jorgensen JL, et al. . The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014;14(4): 319-326. - PMC - PubMed
    1. Bar M, Wood BL, Radich JP, et al. . Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leukemia Res Treat. 2014;2014:421723. - PMC - PubMed

Publication types

MeSH terms

Associated data